Dual Bronchodilation With Qva149 Reduces COPD Exacerbations: The Spark Study

被引：0
|
作者：
Wedzicha, J. A. [1 ]
Decramer, M. [2 ]
Ficker, J. [3 ]
Taylor, A. Fowler [4 ]
D'Andrea, P. [4 ]
Arrasate, C. [4 ]
Berhane, I. [4 ]
Chen, H. [4 ]
Banerji, D. [4 ]
机构：
[1] UCL, London, England
[2] Katolik Univ Leuven, Leuven, Belgium
[3] Klinikum Nuernberg, Nurnberg, Germany
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2428
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dual Bronchodilation With Once-Daily Qva149 Provides Superior Bronchodilation Compared To Its Mono-Components And Tiotropium In All Subgroups Of Patients With COPD: The Shine Study
    Bateman, E. D.
    Welte, T.
    Hashimoto, S.
    Gallagher, N.
    Green, Y.
    Horton, R.
    Henley, M.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [32] impact of tiotropium on exacerbations versus glycopyrronium and QVA149 Response
    Riario-Sforza, Gian Galeazzo
    Ridolo, Erminia
    Riario-Sforza, Edoardo
    Incorvaia, Cristoforo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (06) : 677 - 677
  • [33] Dual bronchodilation and exacerbations of COPD
    Cazzola, Mario
    Ora, Josuel
    Puxeddu, Ermanno
    JOURNAL OF THORACIC DISEASE, 2016, 8 (09) : 2383 - 2386
  • [34] Once-Daily Qva149 Improves Dyspnea, Quality Of Life And Reduces The Rate Of Exacerbations Compared To Tiotropium Plus Formoterol In COPD Patients: The Quantify Study
    Korn, S.
    Gebner, C.
    Schurmann, W.
    Forster, K.
    Sieder, C.
    Hiltl, S.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [35] Qva149 Once Daily Is Safe And Well Tolerated In Patients With COPD: The Shine Study
    Welte, T.
    Barnes, N.
    Nagase, T.
    Gallagher, N.
    Green, Y.
    Horton, R.
    Henley, M.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [36] QVA149 provides superior peak lung function in patients with COPD
    Barnes, Neil
    Hashimoto, Shu
    Nagase, Takahide
    Chen, Hungta
    Gallagher, Nicola
    D'Andrea, Peter
    Alagappan, Vijay
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [37] LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Humphries, Michael
    Wang, Linda
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1015 - 1026
  • [38] Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study
    Beeh, Kai-Michael
    Korn, Stephanie
    Beier, Jutta
    Jadayel, Dalal
    Henley, Michelle
    D'Andrea, Peter
    Banerji, Donald
    RESPIRATORY MEDICINE, 2014, 108 (04) : 584 - 592
  • [39] Once-daily QVA149 improves symptom scores in patients with COPD
    Welte, Tobias
    Dahl, Ronald
    Gallagher, Nicola
    D'Andrea, Peter
    Alagappan, Vijay
    Banerji, Dona
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [40] Qva149 Once Daily Is Safe And Well Tolerated In Patients With COPD: The Illuminate Study
    Vogelmeier, C.
    Bateman, E. D.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
12345